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Summary.-The soluble oestrogen-receptor content of common breast tumours has
been measured by 5 different laboratories, each using their own assay procedure.
Good agreement was achieved on whether a sample was positive or negative for
oestrogen receptor. Qualitative differences between laboratories could be explained
by differences in thiol-reagent content of assay medium and by the method of homo-
genization. Recommendations are made on some ofthe factors involved in the routine
assay of receptors in breast tumours.
A PUBLICATION in 1975 (McGuire et al.,
1975) pointed to theprognostic significance
of soluble oestradiol receptor (ER) in de-
termining the likely response of breast
tumours to endocrine therapy, in a retro-
spective survey of patients with advanced
breast cancer.
In parallel to the prospective clinical
studies set up by the British Breast Group
(BBG) (Roberts et al., 1978) it was decided
to check methodological aspects of ER
assays for the following reasons. (1) The
clinical data for the BBG study would
come from more than one institute and it
was therefore important to check that the
assay methods gave comparable results.
(2) There is a growing world-wide im-
portance ofER measurements in the man-
agement of advanced breast cancer, but
no commonly agreed methodology; com-
parison of the results obtained with com-
mon tissue samples by several laboratories
might facilitate the establishment of a
common methodology.
MATERIALS AND METHODS
Participating groups, together with the
code number used in the tables were: (1) Im-
perial Cancer Research Fund, London;
(2) Biochemistry Department, Glasgow Uni-
versity; (3) Tenovus Institute for Cancer Re-
search, Cardiff; (4) Clinical Surgery Depart-
ment, Edinburgh University; (5) Clinical
Research Laboratories, Christie Hospital,
Manchester. The data for the clinical study
were provided by Groups 1 and 4. Solid tissue
was divided into pieces by a pathologist at the
time of mastectomy, frozen on solid CO2 and
despatched by trainfronm London in insulated
containers, containing solid CO2. The samples
to be analysed in London were stored in the
same way for 6-10 h. Each laboratory used
its own assay method, details ofwhich will be
found in Roberts et al. (1978). The major
differences in methodology used by the parti-
cipating groups are summarized in Table 1
and will be discussed below. For comparative
purposes, the data for all groups have been
expressed on a protein basis.
RESULTS AND DISCUSSION
The results are presented in Table II
and should be considered in the light of 2
questions.
Firstly, if one takes a valueof 5 fmol/mg
protein as being the dividing line between
positive and negative, how well do the
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-Pre'cis of methods used by the tumours is the single most important
participating groups factor in determining response to therapy.
Group On the basis that if 3 or more laboratories
1 2 3 4
5 agreed on the positivity/negativity of a
Pul- sample, that was the true ER content, all
verize laboratories agreed on at least 6 of the 7
eniza- and samples. Ofthe 7 positive tumours, no one
tion Pul- Ultra- homo- Silver- Pul- pstv e ethod verize turrax genize son verize group disagreed more than once. This ob-
osol servation is reassuring, but also indicates
ng/g that occasional (less than 1 in 7) "false
on 20 18 40 50 12 negative" results may be obtained regard-
2 x 103 104 105 2 x 103 105 less of methodology. This result could
its yes yes no no yes explain the approximately 10% of ER-
con- tumours that respond to endocrine is
3timate therapy. All groups agreed on 2 of the 3
ites single mul- mul- mul- mul- negative samples. In the third sample,
5 nM tiple tiple tiple tiple neaies groups l and 2 found values of 10 and 75
details of the methods used by the 5
be found in McGuire et al. (1975). fmol/mg protei respectively. We cannot
distinguish between the possibility that
II.-Oestradiol-receptor values this third sample contained heterogenous
ned by 5 different instittions areas ofpositive andnegative cells, or that
Mean Group 2 groups genuinely obtained a "false
value, --k -i` positive" result. It is noteworthy that
fmol/ 1 2 3 4 5 Groups 1 and 4, who contributed the data
mg of mean value
rotein for the clinical study, agreed on all the
positive tumours.
315 1-3 1-2 0-4 0 4 1-7 The second question concerns the abso-
272 1 1 1 8 06 60 5 02-M lute values ofER obtained by each group. 249 1-2 1-2 0-4 0-3 NM
204 1-4 1-8 0 3 x 05 Important differences, apparently related
146 1*2 1*7 0-9 0-3 1*3 to the presence or absence ofthiol reagents
86 018 1N2 NM 0-7 102 and method ofhomogenization were noted
1-3 1-5 0N7 074 092 (Table II). There was no significant differ-
0-3 013 0-4 0.2 0.6 ence between results obtained by Groups
1 and 2 (bothusing thiolreagents) butthey
NM P P NM NM NM obtained significantly higher values (P< 0-02 in all comparisons) than those ob-
NM NM NM NM NM NM tained by Groups 3 and 4 (no thiol re-
NM NM NM NM NM NM agents). Group 5, which also used thiol
measurable (<5 fmol/mg protein). reagents, obtained intermediate results. It
holimg protein, representing a minimal is therefore recommended that thiol re-
ve (Group = 10fmol/mg protein; Group agents be added. The method of homo-
(mg protein). genization also influences results when
adenocarcinoma; Node metastatic expressed on a protein basis. Vigorous
evalues only. methods of homogenization give high
3on 1 v 3, P< 0*02; 1 v 4, P< -002; yields ofprotein (Groups 3 and 4, Table I)
0-01; 2 v 4, P< 0 001. All other com- w m n
t significant. which may not be accompamed by m-
creased ER release, due to disruption of
ies agree? This is an important ER-poor tissue components. If results are
aspublished data (McGuire et al., expressed on a tissue-weight basis (as
berts etal., 1978) indicate that the favoured by Group 4) protein yield is not
in between positive and negative a problem.
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Although the pathologist judged all
samples to contain adequate malignant
tissue, tumour heterogeneity may account
for some of the variation in results ob-
tained (Hawkins et al., 1977).
Some other conclusions ofthis collabora-
tive project published in detail elsewhere
(King et al., 1978) were: (1) Short
periods of storage on solid CO2 were
satisfactory but liquid N2 refrigeration
was desirable. Storage or transport of
specimens at O-4°C was detrimental.
(2) More variable results were obtained
when cytosol rather than solid tumour was
stored. Tissue should therefore be stored
or transported as solid tumour. (3) Tumour
disruption was probably best achieved by
pulverization. (4) High-speed centrifuga-
tion was not necessary. (5) Dilute cytosols
(<1 mg protein/ml) tended to give low,
or negative, ER values. (6) Cytosol pro-
tein or wet-weight measurements were an
adequate basis for expressing results.
We have shown that there is good quali-
tative agreement between centres. Quan-
titatively there were differences, and some
ofthe key factors influencing the ER levels
have been identified. It may, therefore,
now be possible to standardize methodol-
ogy and obtain comparable results be-
tween different laboratories. We feel that
the results published here will be of use to
laboratories about to set up ER assays,
and also to clinicians wishing to interpret
results obtained with such assays.
We are grateful to Dr Rosemary M. Millis (Guy's
Hospital) for carrying out, the division of tumours
and checking their pathology.
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